GH

Guardant Health, Inc. is a precision oncology company focused on developing and commercializing blood-based liquid biopsy tests for cancer screening, diagnosis, and treatment monitoring. The company's flagship products include Guardant360, a comprehensive genomic profiling test for advanced cancer patients, and Guardant Reveal for minimal residual disease detection and recurrence monitoring. Guardant's Shield test is a blood-based screening solution for colorectal cancer in average-risk individuals. The company's liquid biopsy platform analyzes circulating tumor DNA (ctDNA) in blood samples, offering a less invasive alternative to traditional tissue biopsies. Guardant Health is at the forefront of precision medicine, partnering with pharmaceutical companies and healthcare providers to improve cancer outcomes.